Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 3
1967 1
1968 3
1970 3
1971 3
1974 2
1975 2
1976 1
1979 3
1980 1
1981 1
1982 2
1983 1
1985 1
1988 2
1989 5
1990 5
1991 2
1992 5
1993 3
1994 3
1995 6
1996 8
1997 3
1998 5
1999 6
2000 7
2001 8
2002 2
2003 7
2004 6
2005 6
2006 5
2007 3
2008 6
2009 14
2010 9
2011 11
2012 16
2013 12
2014 15
2015 15
2016 15
2017 12
2018 14
2019 19
2020 27
2021 36
2022 30
2023 12
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Results by year

Filters applied: . Clear all
Page 1
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM).
Berardi R, Parisi A, Maruzzo M, Bellani M, Beretta GD, Boldrini M, Cavanna L, Gori S, Iannelli E, Mancuso AM, Marinelli M, Martinella V, Musso M, Papa R, Russo A, Tarantino V, Taranto M, Cinieri S. Berardi R, et al. Among authors: musso m. Support Care Cancer. 2024 Aug 26;32(9):613. doi: 10.1007/s00520-024-08786-8. Support Care Cancer. 2024. PMID: 39222131 Free PMC article.
Time to bury the chisel: a continuous dorsal association tract system.
van den Hoven E, Reisert M, Musso M, Glauche V, Rijntjes M, Weiller C. van den Hoven E, et al. Among authors: musso m. Brain Struct Funct. 2024 Sep;229(7):1527-1532. doi: 10.1007/s00429-024-02829-w. Epub 2024 Jul 16. Brain Struct Funct. 2024. PMID: 39012483 Free PMC article.
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Carrabba MG, Cutini I, Martino M, Dodero A, Bonifazi F, Santoro A, Sorà F, Botto B, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Ladetto M, Cavallo F, Massaia M, Arcaini L, Pennisi M, Zinzani PL, Miceli R, Corradini P. Stella F, et al. Among authors: musso m. Blood Cancer Discov. 2024 Sep 3;5(5):318-330. doi: 10.1158/2643-3230.BCD-24-0052. Blood Cancer Discov. 2024. PMID: 38953781 Free PMC article.
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
Fazio F, Petrucci MT, Corvatta L, Piciocchi A, Della Pepa R, Tacchetti P, Musso M, Zambello R, Belotti A, Bringhen S, Antonioli E, Conticello C, Renzo ND, De Stefano V, Musto P, Gamberi B, Derudas D, Boccadoro M, Offidani M, Morè S. Fazio F, et al. Among authors: musso m. EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. EJHaem. 2024. PMID: 38895069 Free PMC article.
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
Barone A, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Barbui AM, Farina M, Brunello L, Di Chio MC, Novo M, Musso M, Olivieri J, Trotta GE, Dodero A, Aiello A, Corradini P. Barone A, et al. Among authors: musso m. Br J Haematol. 2024 Jun 15. doi: 10.1111/bjh.19590. Online ahead of print. Br J Haematol. 2024. PMID: 38877876 Free article.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Vigna E, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pettine L, Vincelli ID, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Reddiconto G, Maroccia A, Franceschini L, Bertuglia G, Nappi D, Barbieri E, Gamberi B, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P, Gentile M. Martino EA, et al. Among authors: musso m. Hematol Oncol. 2024 Jul;42(4):e3290. doi: 10.1002/hon.3290. Hematol Oncol. 2024. PMID: 38818978
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, Gentile M, Pastore D, Nigro LL, Selleri C, Serio B, Calafiore V, Patti C, Mauro E, Vetro C, Maugeri C, Parisi M, Fiumara P, Parrinello L, Marino S, Scuderi G, Garibaldi B, Musso M, Renzo ND, Vigna E, Martino EA, Raimondo FD, Milone G. Leotta S, et al. Among authors: musso m. Ann Hematol. 2024 Sep;103(9):3701-3712. doi: 10.1007/s00277-024-05725-9. Epub 2024 Apr 13. Ann Hematol. 2024. PMID: 38609726
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: musso m. Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109. Haematologica. 2024. PMID: 38497158 Free PMC article. Clinical Trial. No abstract available.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Dodero A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Chiappella A, et al. Among authors: musso m. Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. Leukemia. 2024. PMID: 38459167 Free PMC article.
350 results